| Full text | |
| Author(s): |
Fernandez Nunez, Eutimio Gustavo
[1, 2]
;
Calil Jorge, Soraia Attie
[3]
;
Astray, Renato Mancini
[3]
;
de Rezende, Alexandre Goncalves
[3]
;
Vale da Costa, Bruno Labate
[4]
;
Ventini Monteiro, Daniella Cristina
[3, 1]
;
Pereira, Carlos Augusto
[3, 1]
;
Tonso, Aldo
[1]
Total Authors: 8
|
| Affiliation: | [1] Univ Sao Paulo, Escola Politecn, Dept Engn Quim, Lab Celulas Anim, Sao Paulo - Brazil
[2] Univ Estadual Paulista Julho de Mesquita Filho, Fac Ciencia & Letras, Dept Ciencias Biol, Assis, SP - Brazil
[3] Inst Butantan, Lab Imunol Viral, Sao Paulo - Brazil
[4] Inst Pesquisas Tecnol Estado Sao Paulo SA, Nucleo Bionanomanufatura, Lab Biotecnol Ind, Sao Paulo - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Brazilian Archives of Biology and Technology; v. 56, n. 5, p. 859-866, SEP-OCT 2013. |
| Web of Science Citations: | 1 |
| Abstract | |
The number of biopharmaceuticals for medical and veterinarian use produced in mammalian cells is increasing year after year. All of them are obtained by stable recombinant cell lines. However, it is recognized that transient gene expression produces high level expression in a short time. In that sense, viral vectors have been extensively used for producing recombinant proteins on lab-scale. Among them, Semliki Forest virus is commonly employed for this purpose. This review discusses the main aspects related to the use of Semliki Forest virus technology as well as its advantages and drawbacks which limit currently its utilization in biopharmaceutical industry on large-scale. (AU) | |